Navigation Links
Transgenomic Reports Third Quarter Financial Results
Date:11/15/2010

of last year. The pipeline of proposals submitted to pharmaceutical companies stood at $7.0 million as of September 30, compared with $6.0 million as of June 30, and $2 million as of March 31, 2010. Existing signed contracts have approximately $1.7 million of potential net sales remaining.  We believe that we are very well positioned to benefit from the growing use of biomarker discovery in the treatment of patients.

"Along with our licensing partner, IntegraGen, we continued to market our new ARISk™ test, which determines if there is an increased risk of autism in a newborn with an autistic older biological sibling.  This test gives us the opportunity to derive revenues through both the kit sales and from performing this assay in our CLIA-certified laboratory.

"We continue to rightsize our operational footprint by consolidating our research and development activities in Omaha, Nebraska, reducing headcount and eliminating open positions.  Although there will be some one-time costs for these measures, these actions are expected to allow us to be cash flow positive in 2011," Mr. Tuttle concluded.

Conference CallManagement will discuss third quarter 2010 financial results and answer questions during a conference call to be held Monday, November 22, 2010 beginning at 5:00 p.m. Eastern time. To access the call via telephone, please dial 888-563-6275 (domestic) or 706-643-3137 (international) and enter conference ID number 24244484.  The call also will be broadcast live over the Internet. To listen to the webcast, please log onto the Company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions. An archived webcast of the call will be available for 30 days. Investors can listen to a replay via telephone until 11:59 p.m. Eastern time on Wednesday, December 22, 2010 by dialing 800-642-1687 (domestic) or 706-645-9291
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
2. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
3. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
4. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
5. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
6. Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
7. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
8. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
9. Transgenomic, Inc. Reports Third Quarter 2009 Results
10. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
11. Transgenomic, Inc. Reports Second Quarter 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PA (PRWEB) January 15, 2014 The Pittcon ... publisher of Food Safety Tech , an e-Journal and ... signed an agreement for the second year for the co-location ... Pittcon 2014. The partnership provides that the registration fee to ...
(Date:1/15/2014)... MINNEAPOLIS , Jan. 15, 2014 ­ RedBrick ... and behavior change technology, today announces that EmblemHealth ... insurer and wellness company, is now providing the RedBrick ... digital coaching program, to all of its members. EmblemHealth ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... -- Spectrum Equity Investors of Boston will become the ... national provider of technology to mortgage lenders. , , ... an $84 million recapitalization of Mortgagebot. , ,Following the ... join Mortgagebot's board of directors. Terms of the transaction ...
... -- Metavante Corp., the financial technology subsidiary of Marshall ... of Nashville, Tenn., The company will continue to operate ... subsidiary of Metavante , with existing management continuing ... the transaction were not disclosed. , ,LINK2GOV provides ...
... The WiCell Research Institute's announcement Monday that it has ... to create the nation's first National Stem Cell Bank ... and innovative approach to the new field of research. ... opposition to embryonic stem cell research, the path forward ...
Cached Biology Technology:Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot 2Metavante acquiring LINK2Gov 2WiCell to host new national stem cell bank 2WiCell to host new national stem cell bank 3WiCell to host new national stem cell bank 4
(Date:7/9/2014)... considered a healthy source of protein, that,s not why the ... be presented at Tops Club Inc.,s annual International Recognition Days ... are 20-something women who want dishes that are quick, easy ... "They basically seem to care less about any health benefits ... it to look good and because it,s quick to cook ...
(Date:7/9/2014)... , an associate professor of plant pathology and ... been awarded the 2014 Alexopoulos Prize by ... to advancing the science of mycology the study ... yeasts, lichens, plant pathogens, and medically important fungi. , ... outstanding early-career mycologist. Stajich received the award last month ...
(Date:7/9/2014)... 2014) Emerging fungal pathogens pose a greater ... causing population declines of amphibians, bats, corals, bees ... South Florida published in the prestigious journal ... or immunological resistance to a deadly chytrid fungus ... "Acquired resistance is important because it is the ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2USF study: Amphibians can acquire resistance to deadly fungus 2
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2010.   Revenues for the third quarter of ... million in the same quarter last year. Net income for the ... These results compared to a net loss of $1.1 million, or ...
... BOSTON The discovery that a protein called Rictor plays ... AKT oncogene could provide scientists with a new molecular target ... September 2010 issue of the journal Molecular Cell , ... Medical Center (BIDMC). The oncogenic cousin, known as ...
... Nanomedicine Center for Nucleoprotein Machines has received an award ... its renewal by the National Institutes of Health (NIH). ... of a clinically viable gene correction technology for single-gene ... disease. Sickle cell disease is a genetic condition ...
Cached Biology News:Aware, Inc. Reports Third Quarter 2010 Financial Results 2Aware, Inc. Reports Third Quarter 2010 Financial Results 3Aware, Inc. Reports Third Quarter 2010 Financial Results 4Aware, Inc. Reports Third Quarter 2010 Financial Results 5Rictor protein offers scientists a new molecular target for cancer therapies 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 2NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 3NIH renews Nanomedicine Center focused on treating single-gene disorders for $16.1 million 4
... 14 3C protease from human rhinovirus (HRV ... Novagen brand line of restriction grade proteases. ... recombinant 6XHis-fusion protein, which recognizes the same ... The small, 22 KDa size of the ...
...
... a tradition of progressive centrifuge design and ... The Centra-CL3 and Centra-CL3R (refrigerated) general purpose ... Quality Control Over Sample Preparation , ... up to 99 protocols and has speed ...
PP2B-Abeta (C-20)...
Biology Products: